Rheumatoid Arthritis

Indicated for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies

May be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs)

2 mg PO qDay

Alopecia Areata

Indicated for adults with severe alopecia areata

2 mg PO qDay; increase to 4 mg qDay if inadequate response

With nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider 4 mg qDay

Once adequate response achieved with 4 mg/day, decrease to 2 mg/day

COVID-19

Indicated for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)

4 mg PO qDay

Recommended treatment duration is 14 days or until hospital discharge, whichever comes first